Clinical Trials in Detroit

Showing 6241-6260 of 19,719 trials

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

NCT03634540

This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and cabozantinib will be administered orally once daily.

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell Carcinoma (ccRCC)Kidney Cancer+6 more

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)118 participantsStarted Sep 2018

Los Angeles, California, United States • Los Angeles, California, United States • Miami, Florida, United States +7 more locations

TERMINATEDPhase 213 miles

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

NCT04492722

The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.

Chronic Kidney Disease

AstraZeneca613 participantsStarted Oct 2020

Canoga Park, California, United States • La Mesa, California, United States • San Carlos, California, United States +108 more locations

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Find Trials by Condition in Detroit

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

CYPRESS Efficacy and Safety Study Extension

Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab

InterStim Micro Post Market Clinical Follow-up Study (ELITE)

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

Chimney EndoVascular Aneurysm Sealing Of New Expanded Indication

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes

Oral ONC201 in Adult Recurrent Glioblastoma

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Global Fenestrated Anaconda Clinical STudy